Treating Macular Degeneration
There are two treatable types of age related macular degeneration. The most common type is called age related macular degeneration or AMD. The second type is called wet macular degeneration, and it comprises a much smaller percentage of the cases. Since wet macular degeneration involves the formation of new blood [...]
The Burrill Report submits: By Kristi Eaton A new study shows that a cancer drug is no different in effectiveness as a gold standard for macula degeneration. Researchers from Boston University School of Medicine and the VA Boston Healthcare System discovered there was no difference in efficacy between Genentech’s (now Roche’s ( RHHBY.PK )) Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration after six months. Complete Story »
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
The most common cause of blindness in the elderly is age-related macular degeneration, or AMD. In cases of “wet AMD,” abnormal blood vessels grow behind the retina and leak blood and fluid, resulting in rapid sight loss. …
Macular Degeneration. Avastin. n/a. not specified. Calcium. n/a. ^Back to Content. 251 related reports are studied for females and males at all ages: Comparison with the patient’s adverse outcomes: Name, Count (% of total reports) …
